Last week’s Drug Repositioning Summit was attended by more than 150 people. The Summit started with my 3-hour workshop on 505(b)(2) drug development. Several attendees were seemingly confused about what “drug repositioning” means. There are two distinct ‘flavors’ of drug repositioning:
Take a currently US-approved drug and make significant changes to it (formulation, dose, route of [...]
